Plasma levels of MMP-2, MMP-7, and MMP-9 and their tissue inhibitor TIMP-2 were measured in 89 patients with gastric cancer and the relationship between these parameters and the main clinical morphological characteristics of the disease was analyzed. Plasma levels of the proteins were measured using standard direct ELISA kits. The level of MMP-7 in patients with gastric cancer was significantly higher than in the control group (medians 2.7 and 1.2 ng/ml, respectively; p<0.01), but only in 51% patients this parameter surpassed the upper threshold normal value (2.35 ng/ml; 95% percentile of control). The level of MMP-9 in gastric cancer patients was lower than in control group by 1.6 times (medians 167 and 267 ng/ml, respectively; p<0.01). Plasma levels of MMP-2 and TIMP-2 in patients with gastric cancer and healthy subjects were similar. No appreciable associations of plasma matrixins and TIMP-2 with the main clinical morphological characteristics of the disease were detected. The patients were followed up for 8 to 85 months (median 70.8 months). Low level of MMP-2 and high level of MMP-7 in the plasma proved to be unfavorable prognostic factors for overall survival. At MMP-2<268 ng/ml, the 5-year overall survival was 32% vs. 60% for patients with the marker level higher than this threshold value (p=0.016). The differences in overall survival in relation to their MMP-7 levels for 5-year observation did not surpass 16% (39% at marker level >2.7 ng/ml and 55% at lower level; p=0.048). Plasma levels of MMP-2 and TIMP-2 were not significantly associated with overall survival. Multivariate analysis showed that only T index (p=0.034) and plasma MMP-7 level (p=0.007) were essential for overall survival. The increase in plasma or serum MMP-7 levels is a universal phenomenon in tumors of different histogenesis, which precluded the use of this parameter as a specific diagnostic marker of gastric cancer. At the same time, it could be useful for monitoring the treatment efficiency and detection of relapses. In addition, high plasma level of MMP-7 remained an independent factor of unfavorable prognosis for overall survival of patients with gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gershtein ES, Mushtenko VV, Korotkova EA, Bezhanova SD, Morozov AA, Alferov AA, Kazantseva IA, Kushlinskii NE. Matrix metalloproteinases 2, 7, 8, 9 and their type 1 tissue inhibitor in serum of renal cancer patients: clinical and pathologic correlations. Al’manakh Klin. Med. 2017;45(2):94-101. Russian.
Kushlinskii NE, Babkina IV, Kuznetsov IN, Korotkova EA, Ten EA, Bulycheva IV, Solovev YuN, Aliev MD. Tumor-associated metalloproteinases in serum of primary bone sarcoma patients. Mol. Med. 2014;(1):43-46. Russian.
Kushlinskii NE, Gershtein ES. Matrix metalloproteinases and plasminogen activation system components in pathogenesis and clinical course of colorectal cancer. Patogenez. 2013;11(3):4-12. Russian.
Shadrina AS, Tereshkina IV, Plieva YaZ, Kushlinsky DN, Utkin DO, Morozov AA, Filipenko ML, Kushlinsky NE. Matrix metalloproteinases: structure, functions and genetic polymorphism. Patogenez. 2017;15(2):14-23. Russian.
Chen J, Chen LJ, Zhou HC, Yang RB, Lu Y, Xia YL, Wu W, Hu LW. Prognostic value of matrix metalloproteinase-9 in gastric cancer: a meta-analysis. Hepatogastroenterology. 2014;61(130):518-524.
Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta. 2010;1803(1):103-120.
Gerstein ES, Sini L, Ryabov AB, Dvorova EK, Yurchenko AA, Stilidi IS, Kushlinskii NE, Davydov MI. Comparative enzyme immunoassay of matrix metalloproteinases-2, -7, -9 and their tissue inhibitor-2 in tumors and plasma of patients with gastric cancer. Bull. Exp. Biol. Med. 2009;148(6):899-902.
Łukaszewicz-Zając M, Mroczko B, Guzińska-Ustymowicz K, Pryczynicz A, Gryko M, Kemona A, Kędra B, Szmitkowski M. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv. Med. Sci. 2013;58(2):235-243.
Sampieri CL, León-Córdoba K, Remes-Troche JM. Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J. Cancer Res. Ther. 2013;9(3):356-363.
Shen W, Xi H, Wei B, Chen L. The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J. Cancer Res. Clin. Oncol. 2014;140(6):1003-1009.
Soleyman-Jahi S, Nedjat S, Abdirad A, Hoorshad N, Heidari R, Zendehdel K. Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: a meta-analysis. PLoS One. 2014;10(4):e0122316. doi: https://doi.org/10.1371/journal.pone.0122316.
Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin. Cancer Res. 2007;13(7):2054-2060.
Wu W, Yong WW, Chung MC. A simple biomarker scoring matrix for early gastric cancer detection. Proteomics. 2016; 16(22):2921-2930.
Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB, Wu JJ. Elevated serum matrix metalloproteinase-3 and -7 in H. pylorirelated gastric cancer can be biomarkers correlating with a poor survival. Dig. Dis. Sci. 2010;55(6):1649-1657.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 166, No. 9, pp. 347-351, September, 2018
Rights and permissions
About this article
Cite this article
Kushlinskii, N.E., Gershtein, E.S., Ivannikov, A.A. et al. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer. Bull Exp Biol Med 166, 373–376 (2019). https://doi.org/10.1007/s10517-019-04353-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-019-04353-y